An AMCP Market Insights Webinar.

Join us for a webinar on ER+/HER2- Metastatic Breast Cancer, a disease affecting nearly 150,000 people in the U.S. Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care. This session will feature a clinical key opinion leader and payer participants from the roundtable convened by AMCP in February 2025. Presenters will characterize the clinical and QOL burden of ER+/HER2, explore the mechanisms of action of current therapies, review current treatment options, describe therapeutics that targets ERs, and outline payer strategies to facilitate precision oncology care.

In this hour-long webinar, health care attorney Ross Margulies of Manatt, Phelps & Phillips, LLP will review the scope of the April 15^th drug pricing executive order and its impact across various health care stakeholders. We will dive into the background and history of the proposals, many of which are being resurfaced from the first Trump Administration, and talk through the pathway and prospects for these policy proposals.

You get a GLP-1! You get a GLP-1! Everyone gets a GLP-1! This encore presentation of the keynote session at AMCP 2025 delves into the transformative potential of GLP-1 receptor agonists (GLP-1RAs) across a wide range of conditions, including obstructive sleep apnea, binge eating disorder, substance use disorder, NASH, heart failure, osteoarthritis, cystic fibrosis, PCOS, and neurocognitive disorders like Parkinson's and Alzheimer's dementia. Attendees will gain insights into the latest advancements in the GLP-1RA pipeline and explore emerging therapies and their potential to reshape treatment paradigms.

Additionally, this discussion will address key implications for managed care and highlight the challenges in formulary management and benefit design. Join us for an in-depth exploration of these innovative therapies and their potential to revolutionize care across diverse health conditions

A Pre-Approval Information Exchange (PIE) Webinar sponsored by UroGen Pharma, Inc.

This webinar will be hosted by UroGen Pharma, Inc. and will discuss the disease state, product profile, commercialization plans, and clinical information for UGN-102. An investigational drug in development for the treatment of low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC) in adult patients. The safety and efficacy of UGN-102 have not been established by the FDA. This presentation is intended for payors, formulary committees, and similar entities only.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

An AMCP Member Webinar

AMCP is excited to begin a new series of Regulatory Briefing webinars exclusively for AMCP members. Regulatory Briefings will provide an overview of newly proposed regulations and agency guidance relevant to managed care pharmacy. Each webinar will focus on a single rule, breaking down the changes proposed by the agency and any input that the agency is seeking.

In our first webinar, we will be looking at a newly proposed rule from CMS about the Affordable Care Act. Among the topics covered by the proposed rule are, enrollment periods, past due premiums, eligibility for enrollment in QHPs, and essential health benefits.

A Science & Innovation Webinar, presented by Apellis.

Complement 3 Glomerulopathy (C3G) and Primary Immune Complex-mediated Membranoproliferative Glomerulonephritis (IC-MPGN) are two rare, chronic glomerular diseases caused by overactivation of the complement system resulting in severe kidney damage. Webinar topics will include the prevalence, characteristics, and unmet medical needs of patients living with these diseases.
 

A Science & Innovation Webinar, presented by Abbvie.

Psoriasis is a chronic, inflammatory, immunologic condition that primarily manifests on the skin, the body’s largest organ. If not properly treated, uncontrolled psoriasis can induce inflammatory processes beyond the skin and may lead to comorbid disease. Comorbidities that may impact psoriasis patients such as psoriatic arthritis (PsA), cardiovascular disease, metabolic syndrome, inflammatory bowel disease (IBD), depression and others add burden to the entire healthcare system and adversely impact patient outcomes.

An AMCP Webinar, hosted by Formulary Decisions® 

Join us for an interactive, engaging, and informative discussion as we dive into the evolving landscape of pre-approval information exchange (PIE). Our diverse panel of biopharma and market access and communication experts will guide you through a live session filled with valuable insights and strategies for engaging healthcare decision-makers with pre-approval information. We will explore opportunities and innovative solutions for leveraging PIE when collaborating with stakeholders.